CDr10b inhibits the expression of cyclooxygenase-2 and inducible nitric oxide synthase induced by lipopolysaccharide
- Authors
- Gu, Gyo-Jeong; Lim, Se-Jin; Ahn, Sang-il; Lee, Sung-Chan; Chang, Young-Tae; Choi, Tae Hyun; Kim, Byoung Soo; Eom, Yong-Bin; Lee, Na Kyung; Youn, Hyung-Sun
- Issue Date
- 5-Nov-2014
- Publisher
- Elsevier BV
- Keywords
- Inflammation; Nuclearfactor-kappa B; Cyclooxygenase-2; Inducible nitric oxide synthase; CDr10b
- Citation
- European Journal of Pharmacology, v.742, pp 42 - 46
- Pages
- 5
- Journal Title
- European Journal of Pharmacology
- Volume
- 742
- Start Page
- 42
- End Page
- 46
- URI
- https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/11701
- DOI
- 10.1016/j.ejphar.2014.08.036
- ISSN
- 0014-2999
1879-0712
- Abstract
- The pathophysiological processes of inflammation can lead to a host of diseases, such as periodontitis, atherosclerosis, rheumatoid arthritis, and even cancer. The dysregulated inducible nitric oxide synthase ( iNOS) and cyclooxygenase-2 ( COX- 2) activation play important roles in the development of certain inflammatory diseases. Here, we investigated the effects of CDr10b which is originally developed for a microglia staining probe on inflammation, by modulating NF-kappa B activation and iNOS and COX-2 expression induced by lipopolysaccharide (LPS) in murine macrophages. The CDr10b suppressed NF-kappa B activation and iNOS and COX-2 expression induced by LPS. All the results suggest that CDr10b is a promising novel agent for the treatment of inflammatory diseases. (C) 2014 Elsevier B.V. All rights reserved.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medical Sciences > Department of Biomedical Laboratory Science > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.